

Technical Review Panel Member

Curriculum Vitae

Name: **Nicolas Durier**
 Nationality: French
 Additional languages: English, Thai
 Expertise: **HIV**

Qualifications

Qualification	Institution	Department	Year
Medical Doctorate	Faculty of Medicine of the Catholic University of Lille, France		1989-2001
Master in Public Health	London School of Hygiene and Tropical Medicine, London, UK (distance learning)		2006-2008

Employment History

Employer	Position	Place	Year
Full-time employee positions			
Dreamlopmments Social Enterprise and Foundation (DLP)	Founder and General Director	Bangkok, Thailand	2016-present
amfAR - the Foundation for AIDS Research	Director of Research, TREAT Asia program	Bangkok, Thailand, regional position	2011 – 2015
Family Health International (FHI)	Medical Advisor for Research, Asia Pacific	Bangkok, Thailand, regional position	2008-2010
Médecins Sans Frontières (MSF)	Medical Coordinator, China Programs	Beijing, China	2005-2007
Médecins Sans Frontières (MSF)	Medical Coordinator, Thailand Programs	Bangkok, Thailand	2004-2005
Médecins Sans Frontières (MSF)	Medical Coordinator, Malawi Programs	Chiradzulu, Malawi	2002-2003
Médecins Sans Frontières (MSF)	Field Medical Doctor, Thailand HIV Project	Surin, Thailand	2001-2002
Consultant positions, and appointed expert roles			
Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM)	Member of the Technical Review Panel	Bangkok, Thailand	April 2020-present
HIV Netherland Australia Thailand Research Collaboration (HIV NAT)	Research Physician, part-time	Bangkok, Thailand	March 2010-present

BioSense Diagnostics	Medical Advisor, Asia	Bangkok, Thailand	July 2017- April 2018
Drug for Neglected Diseases Initiative (DNDi)	Medical Advisor, Thailand	Bangkok, Thailand	Jan-Nov 2017
Program for Appropriate Technology in Health (PATH)	Consultant, Global Tuberculosis Programs	Bangkok - Thailand, Kinshasa - DRC	Nov 2010- Jan 2011
Stop TB Partnership, New Diagnostics Working Group	Co-Chair, Culture-based Sub-Group	Bangkok, Thailand	Nov 2009- Aug 2012
European and Developing Countries Clinical Trials Partnership (EDCTP)	Reviewer, Clinical Trials	Bangkok, Thailand	April 2009

Relevant Publications

Peer-reviewed articles

26. Wasana Prasitsuebsai, Chuenkamol Sethaputra, Pagakrong Lumbiganon, Rawiwan Hansudewechakul, Kulkanya Chokephaibulkit, Khanh Huu Truong, Lam Van Nguyen, Kamarul Azahar Mohd Razali, Nik Khairulddin Nik Yusoff, Moy Siew Fong, Sirinya Teeraananchai, Jintanat Ananworanich, **Nicolas Durier** & on behalf of the TAPHOD ACASI study group of IeDEA Asia-Pacific. Adherence to antiretroviral therapy, stigma and behavioral risk factors in HIV-infected adolescents in Asia. **AIDS Care** 2018. DOI: 10.1080/09540121.2018.1425363.

25. Pühr R, Wright ST, Hoy JF, Templeton DJ, **Durier N**, et al. Retrospective study of hepatitis C outcomes and treatment in HIV co-infected persons from the Australian HIV Observational Database. **Sex Health**. 2017 May 9. doi: 10.1071/SH16151. [Epub ahead of print]

24. **Durier N**, Yuniastuti E, Ruxrungtham K, Kinh NV, Kamarulzaman A, et al. Chronic hepatitis C infection and liver disease in HIV-coinfected patients in Asia. **J Viral Hepat**. 2017 Mar; 24(3): 187-196.

23. Ku NS, Jiamsakul A, Ng OT, Yuniastuti E, Cuong do D, Lee MP, Sim BL, Phanuphak P, Wong WW, Kamarulzaman A, Zhang F, Pujari S, Chaiwarith R, Oka S, Mustafa M, Kumarasamy N, Van Nguyen K, Ditangco R, Kiertiburanakul S, Merati TP, **Durier N**, Choi JY; TREAT Asia HIV Observational Databases (TAHOD). Elevated CD8 T-cell counts and virological failure in HIV-infected patients after combination antiretroviral therapy. **Medicine**. 2016 Aug; 95(32):e4570.

22. Chen M, Wong WW, Law MG, Kiertiburanakul S, Yuniastuti E, Merati TP, Lim PL, Chaiwarith R, Phanuphak P, Lee MP, Kumarasamy N, Saphonn V, Ditangco R, Sim BL, Nguyen KV, Pujari S, Kamarulzaman A, Zhang F, Pham TT, Choi JY, Oka S, Kantipong P, Mustafa M, Ratanasuwan W, **Durier N**, Chen YM. Hepatitis B and C Co-Infection in HIV Patients from the TREAT Asia HIV Observational Database: Analysis of Risk Factors and Survival. **PLoS One**. 2016 Mar 2;11(3):e0150512.

21. Do TC, Boettiger D, Law M, Pujari S, Zhang F, Chaiwarith R, Kiertiburanakul S, Lee MP, Ditangco R, Wong WW, Nguyen KV, Merati TP, Pham TT, Kamarulzaman A, Oka S, Yuniastuti E, Kumarasamy N, Kantipong P, Choi JY, Ng OT, **Durier N**, Ruxrungtham K. Smoking and projected cardiovascular risk in an HIV-positive Asian regional cohort. **HIV Med**. 2016 Aug;17(7):542-9.

20. Boettiger DC, Khol V, **Durier N**, Law M, Sun LP. HIV viral suppression in TREAT Asia HIV Observational Database enrolled adults on antiretroviral therapy at the Social Health Clinic, the National Center for HIV/AIDS, Dermatology & STDs, Phnom Penh, Cambodia. **Antivir Ther**. 2016 Apr 28. doi: 10.3851/IMP3052. [Epub ahead of print]

19. Jiamsakul A (corresponding author, group authorship article). A Decade of Combination

- Antiretroviral Treatment in Asia: the TREAT Asia HIV Observational Database (TAHOD) Cohort. **AIDS Res Hum Retroviruses**. 2016 Mar 30. [Epub ahead of print]
18. Nick Walsh, **Nicolas Durier**, Giten Khwairakpam, Annette H Sohn, Ying-Ru Lo. The hepatitis C treatment revolution: how to avoid Asia missing out. **Journal of Virus Eradication** 2015; 1: 272–275.
17. Jeong SJ, Italiano CM, Chaiwarith R, Oon Tek N, Sri La Sri Ponnampalavanar S, Jiamsakul A, Saphonn V, Kinh NV, Kiertiburanakul S, Lee MP, Merati TP, Pham TT, Yunihastuti E, Ditangco R, Kumarasamy N, Fu-Jie Z, Wong WW, Sim BL, Pujari S, Kantipong P, Phanuphak P, Ratanasuwan W, Oka S, Mustafa M, **Durier N**, Choi JY. Late presentation into care of HIV disease and its associated factors in Asia: Results of TAHOD. **AIDS Res Hum Retroviruses**. 2015 Sep 28. [Epub ahead of print]
16. Jiamsakul A, Chaiwarith R, **Durier N**, Sirivichayakul S, Kiertiburanakul S, et al. Comparison of genotypic and virtual phenotypic drug resistance interpretations with laboratory-based phenotypes among CRF01_AE and subtype B HIV-infected individuals. **J Med Virol**. 2015 Jul 3. doi: 10.1002/jmv.24320. [Epub ahead of print]
15. Boettiger DC, Kerr S, Ditangco R, Chaiwarith R, Li PC, Merati TP, Pham TT, Kiertiburanakul S, Kumarasamy N, Vonthanak S, Lee CK, Van Kinh N, Pujari S, Wong WW, Kamarulzaman A, Zhang F, Yunihastuti E, Choi JY, Oka S, Ng OT, Kantipong P, Mustafa M, Ratanasuwan W, **Durier N**, Law M; TREAT Asia HIV Observational Database. Tenofovir-based antiretroviral therapy in HBV-HIV coinfection: results from the TREAT Asia HIV Observational Database. **Antivir Ther**. 2015 Jun 12. doi: 10.3851/IMP2972.
14. Boettiger DC, Nguyen VK, **Durier N**, Bui HV, Heng Sim BL, et al. Efficacy of Second-Line Antiretroviral Therapy Among People Living With HIV/AIDS in Asia: Results From the TREAT Asia HIV Observational Database. **J Acquir Immune Defic Syndr**. 2015 Feb 1; 68(2):186-95.
13. Obach D, Yazdanpanah Y, Esmat G, Avihingsanon A, Dewedar S, **Durier N**, et al. How to optimize HCV treatment impact on life years saved in resource-constrained countries. **Hepatology**. 2015 Jan 10. doi: 10.1002/hep.27691. [Epub ahead of print]
12. Kariminia A, **Durier N**, Jourdain G, et al. Weight as predictors of clinical progression and treatment failure: Results from the TREAT Asia Pediatric HIV Observational Database (TAPHOD). **J Acquir Immune Defic Syndr**. 2014 May 27. [Epub ahead of print].
11. Kiertiburanakul S, Boettiger D, Lee MP, Omar SF, Tanuma J, Ng OT, **Durier N**, et al. Trends of CD4 cell count levels at the initiation of antiretroviral therapy over time and factors associated with late initiation of antiretroviral therapy among Asian HIV-positive patients. **J Int AIDS Soc**. 2014 Mar 14; 17:18804.
10. David Heiden, Peter Saranchuk, NiNi Tun, Bertrand Audoin, Jen Cohn, **Nicolas Durier**, Gary Holland, W Lawrence Drew, Ellen 't Hoen. We urge WHO to act on cytomegalovirus retinitis. **The Lancet Global Health**, Volume 2, Issue 2, Pages e76 - e77, February 2014.
9. Lukas Fenner, Marie Ballif, Claire Graber, Venerandah Nhandu, Jean Claude Dusingize, Claudia P. Cortes, Gabriela Carriquiry, Kathryn Anastos, Daniela Garone, Eefje Jong, Joachim Charles Gnokoro, Omar Sued, Samuel Ajayi, Lameck Diero, Kara Wools-Kaloustian, Sasisopin Kiertiburanakul, Barbara Castelnuovo, Charlotte Lewden, **Nicolas Durier**, Timothy R. Sterling, Matthias Egger, for the International epidemiological Databases to Evaluate AIDS (IeDEA). Tuberculosis in antiretroviral treatment programs in lower income countries: availability and use of diagnostics and screening. **PLoS ONE**, 2013 Oct 17; 8(10): e77697.
8. Ford N, Shubber Z, Saranchuk P, Pathai S, **Durier N**, et al. Burden of HIV-related CMV retinitis in resource-limited settings: a systematic review. **Clinical Infectious Diseases** 2013, July 29. [Epub ahead of print]
7. **Nicolas Durier**; Jintanat Ananworanich; Tanakorn Apornpong; Sasiwimol Ubolyam; Stephen J. Kerr; Apicha Mahanontharit; Laurent Ferradini; Kiat Ruxrungham; Anchalee Avihingsanon.

Cytomegalovirus Viremia in Thai HIV-infected Patients on Antiretroviral Therapy: Prevalence and Associated Mortality. **Clinical Infectious Diseases** 2013; doi: 10.1093/cid/cit173

6. Sarman Singh, Parveen Kumar, Shreya Sharma, Francis Mumbowa, Anandi Martin, **Nicolas Durier**. Rapid Identification and Drug Susceptibility Testing of Mycobacterium tuberculosis: Standard Operating Procedure for Non-Commercial Assays: Part 1: Microscopic Observation Drug Susceptibility Assay v2.4.12. **Journal of Laboratory Physicians**, 2012, 4 (2): 101-111.

5. Sarman Singh, Parveen Kumar, Shreya Sharma, Francis Mumbowa, Anandi Martin, **Nicolas Durier**. Rapid Identification and Drug Susceptibility Testing of Mycobacterium tuberculosis: Standard Operating Procedure for Non-Commercial Assays: Part 2: Nitrate Reductase Assay v1.3.12. **Journal of Laboratory Physicians**, 2012, 4 (2): 112-119.

4. Sarman Singh, Parveen Kumar, Shreya Sharma, Francis Mumbowa, Anandi Martin, **Nicolas Durier**. Rapid Identification and Drug Susceptibility Testing of Mycobacterium tuberculosis: Standard Operating Procedure for Non-Commercial Assays: Part 3: Colorimetric Redox Indicator Assay v1.3.12. **Journal of Laboratory Physicians**, 2012, 4 (2): 120-126.

3. **Durier N**, Nguyen C, White LJ (2012) Treatment of Hepatitis C as Prevention: A Modeling Case Study in Vietnam. **PLoS ONE** 7(4): e34548.

2. Moon S, Van Leemput L, **Durier N**, et al. *Out-of-Pocket Costs of AIDS Care in China: Are Free Antiretroviral Drugs Enough?* **AIDS Care**. 2008;20(8):984-94

1. Yang Yu-ning, **Durier Nicolas**, Tang Zhi-rong. *An analysis of antiretroviral therapy outcomes in the Medecins Sans Frontieres/Guangxi Center for Disease Control and Prevention HIV/AIDS Project*. **Chin J Intern Med**, March 2008, 47(3): 228-231. Article in Chinese.

Books and Guidelines

- Member of the Guidelines Development Group. **World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection**. April 2014. Available at: <http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/>
- Member of the Guidelines Development Group. **World Health Organization. Guidelines on scale up of antiretroviral therapy in resource-limited settings:**
 - *Emergency scale-up of antiretroviral therapy (ART) in resource-limited settings: technical and operational recommendations to achieve “3 millions people on ART by 2005”*. <http://whqlibdoc.who.int/hq/2003/9241591382.pdf>. (Chairman of the working group 1 on Essential Care Package).
 - *Scaling up antiretroviral therapy in resource-limited settings: Treatment guidelines for a public health approach. 2003 edition*. <http://whqlibdoc.who.int/publications/2004/9241591552.pdf>

Additional Information